Biotechnology Stocks
31 stocks with valuations in Biotechnology, ranked by margin of safety. Data is educational only.
DRMA
Dermata Therapeutics Inc
$1.17
Fair: $40.10MoS: 3269.9%
SRPT
Sarepta Therapeutics Inc
$17.53
Fair: $33.20MoS: 110.8%
BMRN
BioMarin Pharmaceutical Inc.
$54.70
Fair: $84.20MoS: 51.3%
BIIB
Biogen Inc.
$196.50
Fair: $280.72MoS: 40.3%Conf: medium
GILD
Gilead Sciences, Inc.
$125.59
Fair: $173.57MoS: 38.2%Conf: high
NBIX
Neurocrine Biosciences, Inc.
$158.30
Fair: $210.03MoS: 31.7%
REGN
Regeneron Pharmaceuticals, Inc.
$612.14
Fair: $801.42MoS: 30.9%Conf: high
RARE
Ultragenyx Pharmaceutical Inc
$27.44
Fair: $28.48MoS: 27.1%
INCY
Incyte Corp
$98.27
Fair: $124.49MoS: 23.7%Conf: high
ABBV
AbbVie Inc
$216.50
Fair: $273.86MoS: 20.3%Conf: high
RVMD
Revolution Medicines, Inc.
$162.84
Fair: $178.94MoS: 16.3%
GERN
Geron Corporation
$1.26
Fair: $1.28MoS: 8.4%
LEGN
Legend Biotech Corporation
$27.93
Fair: $36.56MoS: 3.0%
UTHR
United Therapeutics Corporation
$537.41
Fair: $538.86MoS: -1.1%
AMGN
Amgen Inc.
$337.47
Fair: $346.37MoS: -2.5%Conf: high
ALKS
Alkermes plc
$44.36
Fair: $43.16MoS: -2.7%
VRTX
Vertex Pharmaceuticals Incorpor
$444.93
Fair: $428.06MoS: -3.8%Conf: high
PTCT
PTC Therapeutics Inc
$78.92
Fair: $69.63MoS: -5.5%
ALNY
Alnylam Pharmaceuticals Inc
$278.14
Fair: $253.19MoS: -10.5%Conf: high
KRYS
Krystal Biotech, Inc.
$324.75
Fair: $276.03MoS: -15.0%
MRNA
Moderna, Inc.
$63.93
Fair: $44.27MoS: -15.1%Conf: low
ARQT
Arcutis Biotherapeutics, Inc.
$26.21
Fair: $20.63MoS: -19.6%
NTRA
Natera Inc
$220.11
Fair: $169.44MoS: -20.1%Conf: medium
NVAX
Novavax, Inc.
$9.13
Fair: $7.10MoS: -22.9%
FDMT
4D Molecular Therapeutics, Inc.
$9.66
Fair: $6.51MoS: -25.0%
FOLD
Amicus Therapeutics Inc
$14.49
Fair: $9.89MoS: -31.7%
IONS
Ionis Pharmaceuticals, Inc.
$73.96
Fair: $41.11MoS: -44.4%
BBIO
BridgeBio Pharma, Inc.
$66.21
Fair: $35.80MoS: -47.4%
ARWR
Arrowhead Pharmaceuticals, Inc.
$81.72
Fair: $33.51MoS: -56.6%
DAWN
Day One Biopharmaceuticals Inc
$21.52
Fair: $9.18MoS: -57.3%
INSM
Insmed Inc
$97.85
Fair: $9.46MoS: -90.0%
Built by Intrinsic Investor. Data is provided “as-is” and may be delayed or incomplete. Not financial advice.